Business Description
Zevra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US4884452065
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.83 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 1.83 | |||||
Debt-to-EBITDA | -1.03 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -3.13 | |||||
Beneish M-Score | 36.43 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -38.5 | |||||
3-Year EBITDA Growth Rate | 3.4 | |||||
3-Year EPS without NRI Growth Rate | 23.7 | |||||
3-Year FCF Growth Rate | -24.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 85.79 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 68.52 | |||||
9-Day RSI | 61.51 | |||||
14-Day RSI | 59.44 | |||||
6-1 Month Momentum % | 5.26 | |||||
12-1 Month Momentum % | 20.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2 | |||||
Quick Ratio | 2 | |||||
Cash Ratio | 1.62 | |||||
Days Sales Outstanding | 167.08 | |||||
Days Payable | 703.14 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -109.2 | |||||
Shareholder Yield % | -9.03 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.44 | |||||
Operating Margin % | -309.83 | |||||
Net Margin % | -274.1 | |||||
FCF Margin % | -235.13 | |||||
ROE % | -117.77 | |||||
ROA % | -46.14 | |||||
ROIC % | -99.66 | |||||
3-Year ROIIC % | -35.31 | |||||
ROC (Joel Greenblatt) % | -3985.57 | |||||
ROCE % | -57.2 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 12.56 | |||||
PB Ratio | 9.57 | |||||
EV-to-EBIT | -6.66 | |||||
EV-to-Forward-EBIT | -2.97 | |||||
EV-to-EBITDA | -7.11 | |||||
EV-to-Forward-EBITDA | -24.51 | |||||
EV-to-Revenue | 17.1 | |||||
EV-to-Forward-Revenue | 4.36 | |||||
EV-to-FCF | -7.1 | |||||
Earnings Yield (Greenblatt) % | -15.02 | |||||
FCF Yield % | -14.08 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Zevra Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 22.117 | ||
EPS (TTM) (€) | -1.556 | ||
Beta | 0.67 | ||
Volatility % | 51.85 | ||
14-Day RSI | 59.44 | ||
14-Day ATR (€) | 0.266269 | ||
20-Day SMA (€) | 6.495 | ||
12-1 Month Momentum % | 20.48 | ||
52-Week Range (€) | 3.72 - 7.25 | ||
Shares Outstanding (Mil) | 52.62 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Zevra Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Zevra Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Zevra Therapeutics Inc Frequently Asked Questions
What is Zevra Therapeutics Inc(STU:1GDA)'s stock price today?
When is next earnings date of Zevra Therapeutics Inc(STU:1GDA)?
Does Zevra Therapeutics Inc(STU:1GDA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |